Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BLSM

BlossomHill Therapeutics Inc

15.99

Aug 10 • 4:00 PM ET -0.01 (-0.06%)

15.68

Aftermarket • 5:00 PM ET -0.31 (-1.94%)

Healthcare Biotechnology USA Small NASD

Index	-
Market Cap	464.99M
Enterprise Value	628.84M
Income	-
Sales	-
Book/sh	-4.96
Cash/sh	3.99
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	63
IPO	Aug 07, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	4.01
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.37
Current Ratio	7.37
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / No

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	-
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.03%
SMA50	-0.03%
SMA200	-0.03%
Trades

Shs Outstand	30.64M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	16.05 -0.37%
52W Low	15.25 4.85%
Volatility	- -
ATR (14)	1.04
RSI (14)	-
Beta	-
Rel Volume	0.24
Avg Volume	1.76M
Volume	418,320

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	1.52%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	16.00
Price	15.99
Change %	-0.06%

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

PhDJing Rong Jean Cui

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schmid John P.	Director	Aug 10 '26	Buy	16.00	6,000	96,000	6,000	Aug 10 06:35 PM
Chen Bihua	Director	Aug 10 '26	Buy	16.00	312,500	5,000,000	3,614,034	Aug 10 06:32 PM
Keyes Jason A	Chief Financial Officer	Aug 10 '26	Buy	16.00	700	11,200	700	Aug 10 06:27 PM
Liptak Vincent Paul	General Counsel	Aug 07 '26	Buy	15.80	2,500	39,500	109,212	Aug 10 06:26 PM
Liptak Vincent Paul	General Counsel	Aug 10 '26	Buy	16.00	2,200	35,200	111,412	Aug 10 06:26 PM

Open in Screener

EQ

Equillium Inc

2.19

Aug 10 • 3:59 PM ET +0.08 (3.79%)

2.16

Aftermarket • 7:34 PM ET -0.03 (-1.37%)

Healthcare Biotechnology USA Micro NASD

Peers: ACOG CNTB GALT IMUX IPHA KZIA SPRO VRCA AGEN ALPS

| Held by: VTI VXF IWC QQQS AVSC DFMC DFAS

Index	-
Market Cap	138.47M
Enterprise Value	77.84M
Income	-19.05M
Sales	0.00M
Book/sh	0.94
Cash/sh	0.97
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Oct 12, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.33
P/C	2.26
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	18.62
Current Ratio	18.62
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.32
EPS next Y	-0.25
EPS next Q	-0.05
EPS this Y	40.26%
EPS next Y	-7.73%
EPS next 5Y	8.32%
EPS past 3/5Y	40.45% 23.22%
Sales past 3/5Y	- -
EPS Y/Y TTM	18.25%
Sales Y/Y TTM	-100.00%
EPS Q/Q	77.30%
Sales Q/Q	-
Earnings	May 13 AMC
EPS/Sales Surpr.	-31.29% -

Insider Own	20.43%
Insider Trans	-6.47%
Inst Own	57.85%
Inst Trans	15.26%
ROA	-47.75%
ROE	-54.39%
ROIC	-31.90%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-9.05%
SMA50	-19.38%
SMA200	15.97%
Trades

Shs Outstand	63.23M
Shs Float	50.31M
Short Float	11.07%
Short Ratio	6.66
Short Interest	5.57M
52W High	3.54 -38.14%
52W Low	0.46 380.26%
Volatility	6.93% 8.58%
ATR (14)	0.21
RSI (14)	38.53
Beta	1.78
Rel Volume	0.75
Avg Volume	836.63K
Volume	630,262

Perf Week	-0.45%
Perf Month	-24.74%
Perf Quarter	3.79%
Perf Half Y	44.08%
Perf YTD	41.29%
Perf Year	342.25%
Perf 3Y	173.07%
Perf 5Y	-64.04%
Perf 10Y	-
Recom	1.00
Target Price	8.60
Prev Close	2.11
Price	2.19
Change %	3.79%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-13-26	Initiated	Piper Sandler	Overweight
May-28-26	Upgrade	Leerink Partners	Market Perform → Outperform	$6
Apr-23-26	Initiated	Oppenheimer	Outperform	$7
Apr-16-26	Initiated	B. Riley Securities	Buy	$6
Apr-14-26	Initiated	Raymond James	Strong Buy	$6
Apr-07-26	Initiated	Cantor Fitzgerald	Overweight	$10
Mar-13-26	Initiated	Roth Capital	Buy	$12
Feb-25-26	Initiated	Stifel	Buy	$5
Mar-28-25	Downgrade	Leerink Partners	Outperform → Market Perform	$3 → $1
Oct-29-21	Resumed	Stifel	Buy	$12
Sep-15-21	Initiated	Cantor Fitzgerald	Overweight	$14
Jul-14-20	Reiterated	H.C. Wainwright	Buy	$14 → $24
Jul-10-20	Resumed	Stifel	Buy	$22 → $10
Feb-22-19	Initiated	SVB Leerink	Outperform	$16

Show Previous Ratings

Jun-02-26 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.42% +11.47%
May-28-26 04:05PM	Equillium to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) +7.98%
May-20-26 04:05PM	Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis (GlobeNewswire) +16.71% +7.28%
May-13-26 04:01PM	Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +12.12%
May-01-26 04:42PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Loading…
Apr-20-26 04:05PM	Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event (GlobeNewswire) +6.97%
Apr-08-26 08:30AM	Equillium Announces Poster Presentations at IMMUNOLOGY2026, the Annual Meeting of the American Association of Immunologists (GlobeNewswire) -6.25%
Apr-02-26 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-26 04:05PM	Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights (GlobeNewswire) +5.64%
Mar-18-26 08:30AM	Equillium to Participate in the 38th Annual Roth Conference (GlobeNewswire)
Mar-13-26 08:00AM	Equillium Announces $35 Million Financing with RA Capital Management (GlobeNewswire) +19.32%
Feb-25-26 08:30AM	Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
Feb-13-26 01:28PM	Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 Start (MarketBeat)
Feb-02-26 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.34%
Nov-20-25 04:35PM	Equillium to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Loading…
07:30AM	The Zacks Analyst Blog Highlights MS, VOO, SPY, IVV, SPYM, RSP, EQ and EQWL (Zacks)
Nov-13-25 04:05PM	Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update (GlobeNewswire) -9.09% +23.81%
Nov-04-25 08:30AM	Equillium to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.10%
Nov-03-25 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.93%
Oct-27-25 03:56AM	Cipla's flagship respiratory initiative Breathefree broadens its footprint in the UAE (PR Newswire)
Oct-22-25 08:00AM	Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 (GlobeNewswire) -6.52%
Oct-06-25 04:02PM	Equillium Announces Leadership and Corporate Updates (GlobeNewswire) +12.78%
Sep-03-25 04:05PM	Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.72% -6.42%
07:30AM	These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 (Motley Fool)
Aug-29-25 04:03PM	Equillium to Participate in the Cantor Global Healthcare Conference 2025 (Business Wire)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +78.88%
08:30AM	Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic (Business Wire)
Aug-04-25 08:30AM	Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy (Business Wire) -20.66%
Aug-01-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +81.59%
May-06-25 08:00AM	Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists (Business Wire) -8.15%
08:00AM	Loading…
May-01-25 08:00AM	Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 (Business Wire)
Apr-24-25 09:00AM	Equillium Announces Feedback from the U.S. Food and Drug Administration (Business Wire)
Apr-01-25 09:55AM	Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks) +28.42%
Mar-27-25 12:49PM	Equillium pushes for breakthrough status despite missing primary endpoint (Clinical Trials Arena) -35.62%
07:00AM	Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights (Business Wire)
07:00AM	Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease (Business Wire)
Feb-21-25 09:55AM	Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Feb-10-25 12:00PM	Equillium (EQ) Upgraded to Buy: Here's What You Should Know (Zacks) -10.10%
08:50AM	Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Feb-06-25 04:18PM	Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge (GuruFocus.com) +33.03% -9.31%
08:00AM	Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis (Business Wire)
Nov-13-24 04:01PM	Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates (Business Wire) -8.18% -12.33%
08:00AM	Equillium to Present at the Stifel Healthcare Conference (Business Wire)
Nov-12-24 08:00AM	Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer (Business Wire) +13.24%
Nov-06-24 10:00AM	Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth (Zacks)
Oct-31-24 07:00AM	Equillium Maintains Rights to Itolizumab Following Ono Partnership (Business Wire) -37.61%
Oct-07-24 08:00AM	Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (Business Wire) +8.00%
Sep-17-24 11:54AM	Equillium collaborates with Vivtex for oral formulation of autoimmune therapy (Pharmaceutical Technology)
Sep-10-24 08:00AM	Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit (Business Wire)
Sep-04-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-28-24 08:00AM	Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference (Business Wire)
Aug-08-24 05:35PM	Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights (Business Wire)
Aug-06-24 08:00AM	Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease (Business Wire) +14.85%
Jul-18-24 01:57PM	Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance (Business Wire)
Jul-02-24 08:00AM	Equillium to Participate in Upcoming Investor Conferences (Business Wire)
Jun-12-24 08:00AM	Equillium to be included in the Russell Microcap Index (Business Wire)
Jun-05-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -19.08%
Jun-04-24 08:00AM	Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata (Business Wire) -27.89%
May-29-24 08:00AM	Equillium to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.48%
May-14-24 08:00AM	Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease (Business Wire)
May-09-24 10:56PM	EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.88% -15.00%
05:35PM	Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights (Business Wire)
May-07-24 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists (Business Wire)
Apr-03-24 08:00AM	Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.88%
Apr-01-24 10:15AM	Equillium's lupus drug improves kidney biomarker, teeing up opt-in decision from Ono (FierceBiotech.com) -8.66%
08:00AM	Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis (Business Wire)
Mar-25-24 09:53PM	EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -13.48% -15.57%
05:10PM	Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights (Business Wire)
Mar-22-24 08:00AM	Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference (Business Wire)
Jan-29-24 04:07AM	15 Cash-Rich Penny Stocks Hedge Funds Are Buying (Insider Monkey)
Dec-21-23 09:52AM	Equillium swaps multi-cytokine inhibitor for oral option after underwhelming phase 2 data (FierceBiotech.com) -9.57%
08:00AM	Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease (Business Wire)
Nov-20-23 11:23AM	EQ Bank Card launches in Québec as Carte Banque EQ (PR Newswire)
Nov-13-23 09:00AM	Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology (Business Wire)
Nov-08-23 04:01PM	Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (Business Wire)
Nov-06-23 08:00AM	Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology (Business Wire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) -7.52%
Oct-19-23 08:00AM	Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology (Business Wire)
Oct-16-23 08:00AM	Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium (Business Wire) +6.66%
Oct-03-23 08:00AM	Equillium to Host Analyst & Investor Day (Business Wire)
Oct-02-23 08:00AM	Equillium to Present at the JonesTrading 2023 Healthcare Summit (Business Wire)
Sep-20-23 08:00AM	Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences (Business Wire)
Aug-30-23 08:00AM	Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference (Business Wire)
Aug-12-23 08:05AM	Equillium, Inc. (NASDAQ:EQ) Just Reported, And Analysts Assigned A US$6.06 Price Target (Simply Wall St.)
Aug-09-23 05:30PM	Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (Business Wire)
Aug-02-23 04:00PM	Equillium Announces $7.5 Million Share Repurchase Program (Business Wire)
Jun-01-23 08:00AM	Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences (Business Wire)
May-15-23 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists (Business Wire) +16.84%
May-11-23 05:25PM	Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates (Business Wire)
May-03-23 06:14AM	News Flash: Analysts Just Made A Meaningful Upgrade To Their Equillium, Inc. (NASDAQ:EQ) Forecasts (Simply Wall St.)
Apr-24-23 08:00AM	Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation (Business Wire)
Mar-23-23 04:01PM	Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates (Business Wire) +11.54%
Mar-22-23 08:00AM	Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference (Business Wire)
Feb-17-23 08:00AM	Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR (Business Wire)
Feb-07-23 08:00AM	Equillium to Present at the SVB Securities Annual Global Healthcare Conference (Business Wire)

Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March 2017 and is headquartered in La Jolla, CA.

Co-FounderMr. Bruce Steel

Chief Scientific Officer & PresidentDr. Stephen Connelly Ph.D.

P.M.P.Ms. Christine Zedelmayer M.B.A.

Senior VP of Finance & Principal Accounting OfficerMs. Penny Tom CPA

Vice President of Investor Relations & Corporate CommunicationsMr. Michael Moore

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Connelly Stephen	Officer	Jun 05 '26	Proposed Sale	2.94	30,975	91,070		Jun 05 05:07 PM
Zedelmayer Christine	Sr. Vice President and COO	Jun 05 '26	Option Exercise	0.79	14,584	11,448	77,170	Jun 05 04:42 PM
Zedelmayer Christine	Sr. Vice President and COO	Jun 05 '26	Sale	2.93	14,584	42,737	62,586	Jun 05 04:42 PM
Connelly Stephen	President and CSO	Jun 04 '26	Sale	3.16	200,000	632,760	793,000	Jun 05 04:42 PM
Connelly Stephen	President and CSO	Jun 05 '26	Sale	2.94	30,975	91,070	762,025	Jun 05 04:42 PM
Connelly Stephen	Officer	Jun 04 '26	Proposed Sale	3.16	200,000	632,760		Jun 04 05:30 PM
Tom Penny	Principal Accounting Officer	May 28 '26	Option Exercise	0.79	65,000	51,025	65,000	May 29 06:28 PM
Tom Penny	Principal Accounting Officer	May 28 '26	Sale	2.95	65,000	191,750	0	May 29 06:28 PM
Zedelmayer Christine	Sr. Vice President and COO	May 28 '26	Option Exercise	0.77	86,012	66,391	118,390	May 29 06:19 PM
Zedelmayer Christine	Sr. Vice President and COO	May 27 '26	Option Exercise	0.77	9,821	7,562	72,407	May 29 06:19 PM
Zedelmayer Christine	Sr. Vice President and COO	May 28 '26	Sale	2.80	86,012	240,693	62,586	May 29 06:19 PM
Zedelmayer Christine	Sr. Vice President and COO	May 27 '26	Sale	2.70	9,821	26,517	62,586	May 29 06:19 PM
Zedelmayer Christine	Officer	May 27 '26	Proposed Sale	2.63	65,625	172,593		May 27 04:14 PM
Zedelmayer Christine	Sr. Vice President and COO	Mar 13 '26	Option Exercise	0.79	120,312	94,445	182,898	Mar 16 06:53 PM
Zedelmayer Christine	Sr. Vice President and COO	Mar 13 '26	Sale	2.50	120,312	300,816	62,586	Mar 16 06:53 PM
Zedelmayer Christine	Officer	Mar 13 '26	Proposed Sale	2.40	120,312	288,748		Mar 13 04:08 PM
Zedelmayer Christine	Sr. Vice President and COO	Mar 09 '26	Option Exercise	0.79	152,361	119,603	243,805	Mar 11 08:11 PM
Zedelmayer Christine	Sr. Vice President and COO	Mar 09 '26	Sale	2.00	181,219	362,438	62,586	Mar 11 08:11 PM
Zedelmayer Christine	Officer	Mar 09 '26	Proposed Sale	1.77	181,219	320,757		Mar 09 04:07 PM
Zedelmayer Christine	Sr. Vice President and COO	Feb 19 '26	Option Exercise	0.76	185,937	141,750	300,819	Feb 23 12:52 PM
Zedelmayer Christine	Sr. Vice President and COO	Feb 19 '26	Sale	1.76	185,937	328,104	191,444	Feb 23 12:52 PM
Zedelmayer Christine	Officer	Feb 19 '26	Proposed Sale	1.70	185,937	316,092		Feb 19 04:03 PM
Tom Penny	Principal Accounting Officer	Jan 08 '26	Sale	1.29	6,533	8,428	0	Jan 09 05:37 PM
Tom Penny	Officer	Jan 08 '26	Proposed Sale	1.29	6,533	8,427		Jan 08 12:22 PM
Zedelmayer Christine	Sr. Vice President and COO	Dec 23 '25	Option Exercise	0.79	100,000	78,500	191,444	Dec 23 04:24 PM
Zedelmayer Christine	Sr. Vice President and COO	Dec 23 '25	Sale	1.50	100,000	150,000	91,444	Dec 23 04:24 PM
Zedelmayer Christine	Officer	Dec 23 '25	Proposed Sale	1.50	100,000	150,000		Dec 23 04:18 PM
Zedelmayer Christine	Sr. Vice President and COO	Dec 12 '25	Sale	1.34	23,804	31,897	103,344	Dec 15 05:39 PM
Zedelmayer Christine	Sr. Vice President and COO	Dec 15 '25	Sale	1.31	11,900	15,589	91,444	Dec 15 05:39 PM
Zedelmayer Christine	Officer	Dec 12 '25	Proposed Sale	1.34	23,804	31,897		Dec 12 04:01 PM
Zedelmayer Christine	Sr. Vice President and COO	Nov 25 '25	Sale	0.95	8,098	7,696	127,148	Nov 25 06:08 PM
Zedelmayer Christine	Officer	Nov 25 '25	Proposed Sale	0.92	8,098	7,428		Nov 25 02:43 PM

BLSM

BlossomHill Therapeutics Inc

EQ

Equillium Inc

Upgrade your Finviz experience